RISS 학술연구정보서비스

검색
다국어 입력

http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.

변환된 중국어를 복사하여 사용하시면 됩니다.

예시)
  • 中文 을 입력하시려면 zhongwen을 입력하시고 space를누르시면됩니다.
  • 北京 을 입력하시려면 beijing을 입력하시고 space를 누르시면 됩니다.
닫기
    인기검색어 순위 펼치기

    RISS 인기검색어

      검색결과 좁혀 보기

      선택해제

      오늘 본 자료

      • 오늘 본 자료가 없습니다.
      더보기
      • 무료
      • 기관 내 무료
      • 유료
      • KCI등재

        Clinical Effectiveness of a Unani Regimen in the Management of Hasāh al-kuliya (Nephrolithiasis): A Case Report

        Qaiyyum, Ifra Abdul,Nawab, Mohammad Cellmed Orthocellular Medicine and Pharmaceutical 2020 셀메드 (CellMed) Vol.10 No.3

        Hasāh al-kuliya (Nephrolithiasis) is a common disease with a worldwide prevalence of about 12%. A 64 years old male patient, who visited the outpatient department of National Research Institute of Unani Medicine for Skin Disorder (NRIUMSD), Hyderabad, presented with complaints of mild dull pain in right flank region and burning micturition for one month. The ultrasonography of whole abdomen confirmed that there was one stone of 5 mm in calyceal region of each kidney. The patient was treated with the Unani regimen comprising of three formulations Majoon, Hajrul Yahood (5 gm), Jawarish Zarooni Sada (5 gm) and Habb-i-Mudir (1000 mg) for 6 months. The patient did not report any acute pain during the therapy. After 6 months of treatment the ultrasonography of whole abdomen showed absence of the stone from each kidney, ureters and bladder. There was no recurrence of the disease during next 6 months of post treatment follow up. This case report documented the successful medical treatment and prevention of recurrence of bilateral nephrolithiasis through Unani medicines. It concluded that the Unani regimen was effective and safe in the management of bilateral nephrolithiasis.

      • KCI등재

        THE THERAPEUTIC USES AND PHARMACOPEAL ACTION OF JIRJEER (Eruca sativa): A Review

        Qaiyyum, Ifra Abdul,Nergis, Afiya Cellmed Orthocellular Medicine and Pharmaceutical 2022 셀메드 (CellMed) Vol.12 No.2

        The Unani System of Medicine (USM) is one of the traditional systems of medicine that deals with plants. Plants are large source of medicine. JIRJEER (Eruca sativa) is one of the plant origin drugs, has been used for various therapeutic purposes in USM. It contains Erucic acid (major contain), oleic acid, linoleic acid, saturated Fatty acids, Flavonoids, Phenolics, Glucosinolate, Vitamin C and Carotenoids. These active constituents are responsible for their actions described in Unani classical literature such as Muqqawwi-e-bah (Aphrodisiac), Muwallid-e-mani (Spermatomatogenic), Daf-e-sumoom (Antidote), Kasir-e-riyah (Carminative), Jaali (Cleanser/Detergent), Mudirr-e-bawl (Diuretic) wo Mudirr-e-hayd (Emmenogoggue), Muhammir (Rubefacient), Hazim (Digestive), Mulaiyan (Laxative), Muzliq-e-mani (Lubricant), Muddir-e-shir (Galactopoietic), Mufattih-e-Sudad (Deobstruent), Musakhin (Analgesic), Mulattif (Demulcent), Mufattit-i-hasah (Lithotriptic) and whole plant is considered as aphrodisiac. This is a review paper which discusses morphology, pharmacological action, ethno-medicinal and therapeutic uses of this medicinal plant in perspective of Unani medicine. This review has been done through online searches of databases such as PubMed, Google Scholar, Embase, science direct and hand search for classical textbook available in different libraries. It concluded that JIRJEER (Eruca sativa) is one of the best herbal medicines in treatment of Antiulcer, Antibacterial, Fertility, Hepato-protective, Hyperlipidemic, Antioxidant, Antihypertensive, Anti-inflammatory and Anti-edema, Nephro-protective, Antidiabetic, Antifungal and Anticancer properties.

      • KCI등재

        Evaluating Clinical Efficacy and Safety of A Unani Formulation in the Management of Nazla-i-Muzmin (Chronic Rhinosinusitis)

        Kayum, Mohd Abdul,Qaiyyum, Ifra Abdul,Jabeen, Arzeena,Nawab, Mohammad Cellmed Orthocellular Medicine and Pharmaceutical 2021 셀메드 (CellMed) Vol.11 No.2

        Nazla-i-muzmin (Chronic rhinosinusitis) is one of the commonest diseases prevalent all around the world. In India one in eight Indian suffers from this ailment. The current medical management and surgical intervention do not provide complete cure as a result there is a need to search a better alternative drug. The main objective of this study was to evaluate the safety and efficacy of a Unani formulation in the management of chronic rhinosinusitis. This study was designed as a randomised, controlled, parallel group and open label clinical study. It was carried out in 60 participants (30 participants in each group) of chronic rhinosinusitis aged between 18-65 years of either sex. The participants were enrolled based on the symptoms rhinorrhoea, sneezing, facial pain, nasal blockage, post nasal drip and thick nasal discharge. The participants of the test group was treated with a Unani formulation (9 gm) whereas Levocetrizine (10mg) was given to the participants of the control group once at night. In this study the average age of the participants was 30.36 (±10.20) years and 32.63 (±10.97) years in the control and test groups respectively with an average chronicity of 31.26 (± 43.46) months in the control group and 23.86 ± 39.4 months in the test group. The Unani formulation was found effective in reducing rhinorrhoea, sneezing, facial pain, nasal obstruction, post nasal discharge and thick nasal discharge. The snot score at post treatment comparing to the baseline was reduced to 2.1 and 2.0 in the test and control groups respectively. The Unani formulation improved the symptoms of chronic rhinosinusitis in the test group due to the possible action of the ingredients having, deobstruent, anti-inflammatory, concoctive, analgesic, expectorants and antimicrobial activities. It was concluded that the outcome of the study showed the successful management of chronic rhino-sinusitis. The formulation was well tolerated and showed no adverse effect.

      연관 검색어 추천

      이 검색어로 많이 본 자료

      활용도 높은 자료

      해외이동버튼